HBV mutations and their clinical significance

Advances in Medical Sciences

Volumn 57, Issue 1, 2012, Pages 18-22

  Lapinski T W ^a   Pogorzelska, J ^a   Flisiak, R ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

drug resistance; HBV mutations; hepatitis B

Indexed keywords

ADEFOVIR; DNA POLYMERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PROTEIN S; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL ACTIVITY; CANCER PATIENT; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DRUG TREATMENT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IC 50; LIVER CELL CARCINOMA; NONHUMAN; REVIEW; SEROCONVERSION; VACCINATION; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE;

EID: 84865176167     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0006-x     Document Type: Review

References (20)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004 Mar;11(2):97-107.
2. Maddrey WC. Hepatitis B: An important public health issue. J Med Virol. 2000 Jul;61(3):362-6
3. McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010 Aug;14(3):461-76
4. Kane MA. Global status of hepatitis B immunisation.Lancet. 1996 Sep 14;348(9029): 696
5. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988 Oct;69 ( Pt 10):2575-83
6. Lau JY, Wright TL. Molecular virologyand pathogenesis of hepatitis B. Lancet. 1993Nov;342(8883):1335-40
7. Locarnini SA, Yuen L. Molecular genesis of drugresistantand vaccine-escape HBV mutants. Antivir Ther 2010;15(3 Pt B):451-61
8. Clements CJ, Coghlan B, Creati M, Locarnini S,Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? BullWorld Health Organ 2010 Jan;88(1):66-73
9. Asselah T, Lada O, Marcellin P. [Treatment of chronic hepatitis B]. Rev Prat 2011; 61(1):45-51. [Article inFrench]
10. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha- 2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007 May;56(5):699-705
11. Tang H, Raney AK, McLachlan A. Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol. 2001Oct;75(19):8937-48.
12. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009 Nov;137(5):1593-608 e1-2
13. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxilfumarate treatment for chronic hepatitis B. Gastroenterology. 2011 Jan;140(1):132-43.
14. Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C, Bozdayi AM. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol. 2011 Nov 9. [Epub ahead of print]
15. Xu H, Chen Y, He LL, Lei BJ, Lei XZ. [Lamivudineresistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy]. Zhonghua Gan Zang Bing Za Zhi. 2011 Jun;19(6):427-30. [Article in Chinese]
16. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010 Apr;52(4):493-500
17. Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini- Silberstein F, Perno CF. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis. 2011 Dec;43(12):975-83
18. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999 Nov;30(5):1312-7
19. Warner N, Locarnini S. Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma? Antivir Ther. 2009;14(2):139-42
20. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther 2008;13(7):875-9